4D Molecular Therapeutics (NASDAQ:FDMT) Releases Earnings Results, Misses Estimates By $0.02 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) posted its quarterly earnings data on Thursday. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02), FiscalAI reports. The business had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock opened at $11.65 on Friday. 4D Molecular Therapeutics has a one year low of $5.97 and a one year high of $14.00. The stock has a fifty day moving average price of $10.87 and a 200 day moving average price of $9.86. The stock has a market cap of $609.06 million, a P/E ratio of -4.53 and a beta of 2.73.

Wall Street Analyst Weigh In

Several research firms recently commented on FDMT. HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Chardan Capital upgraded shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.62.

Insider Buying and Selling at 4D Molecular Therapeutics

In related news, insider David Kirn sold 12,415 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $10.05, for a total value of $124,770.75. Following the sale, the insider owned 871,737 shares of the company’s stock, valued at $8,760,956.85. The trade was a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Scott Bizily sold 9,810 shares of the stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at $103,404. This trade represents a 53.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 197,226 shares of company stock worth $2,200,677 in the last three months. Insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several large investors have recently modified their holdings of the stock. AQR Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth approximately $46,000. Millennium Management LLC raised its stake in 4D Molecular Therapeutics by 15.0% during the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after acquiring an additional 213,264 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of 4D Molecular Therapeutics during the first quarter valued at $39,000. American Century Companies Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 11.5% during the second quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock valued at $181,000 after acquiring an additional 5,026 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after purchasing an additional 2,284 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.